# HORRAD

Source: https://onco.cc/trials/horrad/  
OnCo record `horrad` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HORRAD found no overall survival benefit from irradiating the prostate in men presenting with bone metastases, though a possible gain in those with few metastases fed into STAMPEDE's later positive finding.

## Summary

HORRAD randomised 432 men with newly diagnosed prostate cancer and bone metastases to androgen deprivation therapy with or without external beam radiotherapy to the prostate. Median overall survival was 45 months with radiotherapy and 43 months without (hazard ratio 0.90, not significant); time to PSA progression improved and a subgroup with fewer than five metastases suggested benefit (Boeve and colleagues, European Urology 2019). STAMPEDE arm H later confirmed a survival gain from prostate radiotherapy in low-volume metastatic disease.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-17
- Tags: radiation-wave4
- Registry id: NCT01053676
- Phase: 3
- Setting: Newly diagnosed prostate cancer with bone metastases: androgen deprivation with or without radiotherapy to the prostate
- Sponsor: Dutch HORRAD study group
- Enrolled: 432
- Result: Median overall survival 45 vs 43 months (hazard ratio 0.90, not significant).

## Sources

- ClinicalTrials.gov NCT01053676: https://clinicaltrials.gov/study/NCT01053676
- European Urology 2019: https://doi.org/10.1016/j.eururo.2018.09.008

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- trials: [STAMPEDE](https://onco.cc/trials/stampede/)

---
JSON: https://onco.cc/api/v1/entities/horrad.json